Immunogenicity and safety of a combined DTPa-IPV/Hib vaccine administered as a three-dose primary vaccination course and a booster dose in healthy children in Russia: a phase III, non-randomized, open-label study

Immunogenicity and safety of a combined DTPa-IPV/Hib vaccine administered as a three-dose primary vaccination course and a booster dose in healthy children in Russia: a phase III, non-randomized, open-label study

We assessed the immunogenicity and safety of the combined diphtheria-tetanus-acellular pertussis-inactivated poliovirus/Haemophilus influenzae type b vaccine (DTPa-IPV/Hib) in children in Russian Federation aiming to support the registration of the vaccine in Russia. In this phase 3, non-randomized,...

Full description

Bibliographic Details
Main Authors: Victor Romanenko, Irina Osipova, Anna Galustyan, Michael Scherbakov, Nathalie Baudson, Déborah Farhi, Luis Anaya, Sherine O. Kuriyakose, Nadia Meyer, Winnie Janssens
Format: Article
Language:English
Published: Taylor & Francis Group 2020-09-01
Series:Human Vaccines & Immunotherapeutics
Subjects:
dtpa-ipv/hib
acellular pertussis
diphtheria
tetanus
poliovirus haemophilus influenzae type b
pediatric population
immunogenicity
safety
reactogenicity
Online Access:http://dx.doi.org/10.1080/21645515.2020.1720437

Similar Items

Similar Items